Drug Profile
Belzutifan - Peloton Therapeutics
Alternative Names: MK 6482; PT-2977; WELIREG; WELIREGTMLatest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator Peloton Therapeutics
- Developer Eisai Inc; Merck & Co; Merck Sharp & Dohme; Peloton Therapeutics
- Class Antineoplastics; Benzonitrile; Fluorobenzenes; Indenes; Small molecules; Sulfones
- Mechanism of Action Endothelial PAS domain-containing protein 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Renal cell carcinoma; Von Hippel-Lindau disease
- Phase II Neuroendocrine tumours; Solid tumours
- Phase I/II Prostate cancer
- Discontinued Iron overload
Most Recent Events
- 18 Mar 2024 Launched for Renal cell carcinoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 23 Feb 2024 Preregistration for Renal cell carcinoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in European Union (PO) prior to February 2024
- 23 Feb 2024 Preregistration for Von Hippel-Lindau disease in European Union (PO) prior to February 2024 (Merck pipeline, February 2024)